Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate

Journal of the Medical Association of Thailand

Volumn 89, Issue SUPPL. 5, 2006, Pages

  Maharom, Pasri ^a   Thamlikitkul, Visanu ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Amphotericin B; Continuous infusion; Infusion related reactions; Nephrotoxicity

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B DEOXYCHOLATE; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CHILL; CLINICAL PRACTICE; CONTINUOUS INFUSION; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE POLICY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHLEBITIS; THAILAND; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WARD;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; MYCOSES; ORGANIZATIONAL POLICY; PROGNOSIS; PROGRAM DEVELOPMENT; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33846651284     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51.
2. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
3. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
4. Richardson MD, Kokki MH. Diagnosis and prevention of fungal infection in the immunocompromized patient. Blood Rev 1998; 12: 241-54.
5. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-66.
6. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005; CD004773.
7. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51: 1-52.
8. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53: 1-112.
9. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-29.
10. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755-61.
11. Grasela TH Jr, Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990; 10: 341-8.
12. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49(Suppl 1): 37-41.
13. Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2006; 25: 138-49.
14. Arning M, Scharf RE. Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989; 67: 1020-8.
15. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75: 476-81.
16. Camp MJ, Wingard JR, Gilmore CE, Lin LS, Dix SP, Davidson TG, et al. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob Agents Chemother 1998; 42: 3103-6.
17. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995; 70: 235-41.
18. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 (Suppl 1): 31-6.
19. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
20. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137: 105-9.
21. Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006; CD004707.
22. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
23. Hiemenz JW. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference? Clin Infect Dis 2003; 36: 952-3.
24. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36: 943-51.
25. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004; 54: 803-8.
26. Uehara RP, Sa VH, Koshimura ET, Prudente FV, Tucunduva LT, Goncalves MS, et al. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundacao ABC. Sao Paulo Med J 2005; 123: 219-22.
27. Banpamai O. Comparison of amphotericin B deoxycholate induced nephrotoxicity between 6-hour versus 24-hour continuous infusion: a randomized controlled trial. Research Report submitted to Infections Diseases Association of Thailand, 2004.
28. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322: 579-82.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
30. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8: iii-iv, 1-72.
31. Gross PA, Pujat D. Implementing practice guidelines for appropriate antimicrobial usage: a systematic review. Med Care 2001; 39: II55-69.